BLRX Market Cap History
Below is a table of the BLRX market cap history going back to 7/17/2019:

Date BLRX Market Cap

Also see: BLRX Shares Outstanding History
and BLRX YTD Return
BLRX Historical Market Cap:
+2.90% CAGR
BLRX Historical Market Cap: +2.90% CAGR

Mouse over chart for data details
BioLineRx is a late clinical-stage biopharmaceutical development company with a focus on oncology. Co.'s development and commercialization pipeline consists of two clinical-stage therapeutic candidates: motixafortide (BL-8040), a peptide for the treatment of stem cell mobilization, solid tumors and acute myeloid leukemia, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, Co. has a therapeutic product called BL-5010 for the treatment of skin lesions. We show 2 historical shares outstanding datapoints in our BLRX shares outstanding history coverage, used to compute BLRX market cap on those dates.

Understanding the changing numbers of shares outstanding, the changing share price, and the resulting changing BLRX market cap history over the course of time is important for investors interested in comparing BLRX's market cap history versus its peers. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies, and then calculating their respective market caps. Comparing the share price of BLRX versus a peer is one thing; comparing BLRX market cap versus a peer is a completely different story. Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares), the market cap for a company like BLRX can fluctuate over the course of history. With this page we aim to empower investors researching BLRX by allowing them to research the BLRX market cap history.
Quotes delayed 20 minutes

Email EnvelopeFree BLRX Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: The Importance of Market Cap

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
BioLineRx (BLRX) is categorized under the Healthcare sector; to help you further research historical market cap numbers, below are some other companies in the same sector:

BLUE Market Cap History
BMEA Market Cap History
BMRA Market Cap History
BMRN Market Cap History
BMY Market Cap History
BNGO Market Cap History
BNTC Market Cap History
BOLD Market Cap History
BOLT Market Cap History
BPMC Market Cap History
More Healthcare companies »


BLRX Market Cap History | | Copyright © 2017 - 2021, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.